Healthcare Industry News:  Kensey Nash 

Devices Personnel

 News Release - February 2, 2006

Rheologics Appoints Dr. Ralph E. Holsworth, Jr. to Management Team

EXTON, Pa.--(HSMN NewsFeed)--Feb. 2, 2006--Rheologics, Inc, a subsidiary of Rheologics Technologies Inc. (OTC: RTGI ) and the developer of the Rheolog(TM), the world's foremost Blood Viscometer, announced today that it has added Dr. Ralph E. Holsworth, Jr. to its Managing Director Team. Prior to joining Rheologics, Dr. Holsworth has served as President of N-ZymeCeuticals, a Colorado-based company involved in the research, development, and distribution of enzyme-related therapeutics. Dr. Holsworth also served as Medical Staff Officer at Jicarilla Indian Health Service, Public Health Service, in Dulce, New Mexico.

Alfonso Knoll, President of Rheologics Technologies, Inc. stated, "We are very excited to have Dr. Holsworth join our team. His first-hand primary care experience, therapeutic, and hemorheology backgrounds, are a perfect fit for Rheologics. In addition, Dr. Holsworth has already introduced the Company to some very interesting, viscosity-lowering compounds that demonstrate a high potential for FDA submission."

Dr. Holsworth noted, "I have been working along side Rheologics for awhile now. I have used the Rheolog extensively as a research device and witnessed first hand its power in helping diagnose a number of subclinical conditions of cardio- and cerebro-vascular disease. In all instances, the conditions were missed by conventional laboratory analyses. This prompted me to want to become directly involved with the Company's future. I am very much looking forward to assisting Rheologics in every way possible."

Rheologics, Inc., is the leader in the study of blood viscosity and its relationship to vascular disease. Founded by Dr. Ken Kensey, an internationally renowned cardiologist, inventor, author, and co-founder of Kensey Nash Corp. (NASDAQ:KNSY ), Rheologics has been testing the Rheolog(TM) with prominent research clinics for over three years and is now positioned to begin commercialization. The Company looks forward to the Rheolog(TM) becoming an invaluable tool in the physician's office, at the bedside, and in the laboratory.

Safe Harbor for Forward-Looking Statements: Except for historical information contained herein, the statements in this Press Release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in the future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, risk inherent in the Company's operations, imprecision in estimating product reserves and the Company's ability to replace and expand its real estate and software interests. Rheologics Technologies, Inc. assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.

Source: Rheologics Technologies

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.